Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
evidence of the efficacy of bevacizumab in patients with HHT.Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations.Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab.Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients.Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time.His hemoglobin levels have remained stable at 14 to 15 g per deciliter.The cost of our patient's regimen (a total of 30 mg per kilogram over four cycles) would be approximately $12,000 today.The costs of continuing the drug in the long term, especially without a Food and Drug Administration-approved indication, would be prohibitive.Our case shows that intermittent dosing allows for long-term, symptomatic improvement and stability of pulmonary arteriovenous malformations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this patient, RDN resulted in a progressive decrease in blood pressure from 161/107 mmHg at baseline to 127/81 mmHg at 12-month follow-up.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“ablation of the renal nerves was also associated with a substantial decrease in muscle sympathetic nerve activity (MSNA), from 56 bursts per minute before RDN to 19 bursts per minute at 12 months after the procedure.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“The hypothesis that renal afferents mediate some of the BP effects of RDN in humans was sparked by the finding that whole-body noradrenaline spillover and MSNA were decreased in a single patient 1 year after RDN170.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [170]
Citations
Cites
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Self-citationNeural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., Hastings, J., Aggarwal, A., & Esler, M. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000103160.35395.9e · Cited by 514
Self-citationNoradrenaline Release and the Pathophysiology of Primary Human Hypertension
Esler, M., Jennings, G., & Lambert, G. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.3.140s · Cited by 138
Self-citation
Cited by
Items 701–763 of 763
Renal sympathetic denervation: renal nerve stimulation
de Jong, M. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.99857558
Acelajado, M. C., & Calhoun, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00031-x · Cited by 1
Giles, T. D., & Materson, B. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00003-x · Cited by 1
Anwaruddin, S., & Bhatt, D. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00028-7
Renal denervation in the treatment of resistant hypertension: a new dawn?
Richter, D., Táborský, M., Fedorco, M., Vindiš, D., Václavík, J., Kociánová, E., Lazárová, M., Ostřanský, J., Sluka, M., Nykl, R., et al. (2019) · Intervenční a akutní kardiologie · doi:10.36290/kar.2019.036
“Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014; 64(7): 644–646.”
BackgroundElectrophysiology and Pathophysiology of the Autonomic Nervous System of the Heart
de Asmundis, C., Camp, G. V., & Brugada, P. (2014) · Springer eBooks · doi:10.1007/978-3-662-45074-1_2
Renal MRI from Niche Application to New Tool in Nephrology
Boer, A. D. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/465
Renal denervation for resistant hypertension: yes
Boschetti, E., Alrashdi, Y., & Schillaci, G. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1429-3
“Subsequent studies have also shown that RDN may reduce the central sympathetic tone, presumably by interrupting renal afferent nerves [14], and improve aortic stiffness [15].”
BackgroundNovel Natriuretic Peptides and the Cardiorenal Syndrome
Martín, F. L., & Burnett, J. C. J. (2010)
Treatment Options in Cardiorenal Syndrome
Berbari, A. E. (2010)
An Update on Catheter-Based Renal Denervation for the Treatment of Hypertension
Wheaten, S. A., Zhang, J., & Stouffer, G. A. (2021) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-021-00682-8
Weber, T., Zweiker, R., Watschinger, B., Grüner, P., Koppelstätter, C., Mc, B., Jh, H., Brussee, H., Hohenstein, K., Lambert, T., et al. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 1
Myat, A., & Bhatt, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5223-1_5
Update Hypertonie: Fokus auf die renale Denervation
Ghorani, H. A., Lauder, L., & Mahfoud, F. (2021) · Kardiologie up2date · doi:10.1055/a-1165-7825
Parati, G., Lombardi, C., & Ochoa, J. E. (2016) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-34141-5_5
Sympathektomie in der Gefäßmedizin
Bürger, T. (2017) · Springer eBooks · doi:10.1007/978-3-662-45856-3_36-1
Khamis, H., Abdelaziz, A., & Ramzy, A. (2013) · The Egyptian Heart Journal · doi:10.1016/j.ehj.2013.08.006 · Cited by 1
Thajudeen, B., Murugapandian, S., & Roy‐Chaudhury, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00072-3
Taking the hype out of hypertension
(2014) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2014.10.0280
Renal Sympathetic Denervation: Using an Old Tool for a New Job?
Healey, J. S. (2013) · Revista Brasileira de Cardiologia Invasiva · doi:10.1016/s0104-1843(13)50002-6
Hameed, M. A., & Dasgupta, I. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_148 · Cited by 2
“and increase renal plasma flow at 30 days after the procedure (Schlaich et al. 2009).”
BackgroundRenal Sympathetic Ablation Using an Irrigated-Tip Catheter: An Attractive Option?
Staico, R., Armaganijan, L., Dietrich, C. D. O., Abizaid, A., Moreira, D. A. R., Lópes, R. D., de Almeida, J. S., & Franco, M. (2013) · Revista Brasileira de Cardiologia Invasiva · doi:10.1016/s0104-1843(13)50004-x
Denervação renal no tratamento de arritmias ventriculares: revisão sistemática e metanálise
Prado, G. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.98.2021.tde-11032022-131041
Role of renal sympathetic denervation in non‑pharmacological treatment of cardiovascular diseases
Bulava, A. (2022) · Intervenční a akutní kardiologie · doi:10.36290/kar.2022.024
Schmieder, R. E. (2023) · CardioVasc · doi:10.1007/s15027-023-2973-1
Devices for the treatment of arterial hypertension
Głuszek, J., & Kosicka, T. M. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0004
Neural Control of Renal Function in Hypertension and Health
Thakare, A. E., Bharshankar, R. N., & Salkar, P. S. (2023) · International Journal of Clinical and Experimental Physiology · doi:10.5530/ijcep.2023.10.1.2
Zeller, C. B. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.98.2023.tde-14072023-081211
DeepADRA2A: predicting adrenergic α2a inhibitors using deep learning
Wankhade, N. V., Dayasagar, U., Sharma, A., Kamble, P., Varma, T., & Garg, P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2270056
“…receptors include alpha a1 (alpha1a (ADRA1A), alpha1b (ADRA1B), alpha1d (ADRA1D)) and alpha a2 (alpha 2a (ADRA2A), alpha 2b (ADRA2B), alpha 2c(ADRA2C)), while the beta-adrenergic receptors consist of beta 1a (ADRB1A), beta 2a (ADRB2A), and beta 3a (ADRB3A) (Devic et al., 2001; Health et al., 2009).”
Hering, D., Heuser, R. R., & Esler, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_2
Self-citationEndpoints for Clinical Effects of Renal Denervation: What Is the Best Surrogate?
Friede, K. A., Fudim, M., & Sobotka, P. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_6
Self-citationPotential Role of Renal Denervation in Management of Atrial Fibrillation
Fischell, T. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_11
Hering, D., & Heuser, R. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_17
Renal denervation for Diabetes and Metabolic syndrome
Carnagarin, R., Kiuchi, M. G., Lugo‐Gavidia, L. M., & Schlaich, M. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_8
Self-citationBertog, S. C., Myat, A., Sharma, A. K., Sievert, K., Piayda, K., Grunwald, I. Q., Reinartz, M., Vogel, A., Pamela, I., Galeru, N., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_4
Device's design and clinical perspectives for resistant hypertension therapy
Jami, O., Allam, O. E., Mohammed, Z., Soulaymane, I., Ilhaam, B. S., Tijani, Y., & Ettahir, A. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200240
“RDN has been shown to reduce blood pressure in animals [40,41] and Human subjects [42 – 44].”
BackgroundTargeting Blood Pressure Lowering and the Sympathetic Nervous System
Hering, D., & Narkiewicz, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00013-1
Bertog, S. C., Vaškelytė, L., Drexel, T., Hofmann, I., Id, D., Gafoor, S. A., Reinartz, M., & Sievert, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-26219-4.00022-0
Study Progress on Renal Sympathetic Denervation in the Treatment of Hypertension
张, 晓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1471979
Oliva, R., Ona, D. I. D., Santos, L. E. G., Punzalan, F. E. R., Tan, J. D., Vilela, G. C., Balmores, B. A., Yap-Uy, K. C., Cawed-Mende, R. M., & Cruz, J. N. (2024) · Philippine journal of cardiology. · doi:10.69944/pjc.f5203e3161
Renal denervation benefits in chronic kidney disease: An updated review
Habas, E. M., Alarbi, K. M. S., Habas, A. M., Baghi, M. A. M., Habas, E., Rayani, A., Said, A., Farfar, K., Errayes, A., Alfitori, G. B., et al. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.004
Li, J., Zhang, X., Jiang, Y., Wang, H., Gao, X., Hu, Y., & Du, B. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00626-z
“Since the initial application of this technique in 2009 [50], RDN has undergone numerous clinical trials and has been validated as an effective modality to treat hypertension, in addition to pharmacologic therapy and lifestyle interventions.”
MethodRenal Artery Denervation: Evidence, Guidelines, and Major Trials
Morariu, P. C., Oancea, A. F., & Floria, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-71930-1_8
Beyond Blood Pressure: Expanding the Use of Renal Denervation in Diverse Pathologies
Burlacu, A., & Brinza, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-71930-1_9
Efficacy of catheter-based ultrasound renal denervation in the treatment of hypertension
Ou, Y.-C., Peng, X., Yang, J.-X., Chen, B., Chen, P., & Liu, M. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i16.102853
“Additionally, it can reduce ventricular remodeling and the risk of adverse events[16].”
Strukturelle Veränderungen des Herzens bei Patienten mit chronischer Nierenerkrankung
Kocaman, H. (2025) · Nephrologie aktuell · doi:10.1055/a-2497-1771
Yonezawa, H., Yamamoto, A., Kageyama, K., Sohgawa, E., Nota, T., Jogo, A., & Miki, Y. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.11.037
Impact of centrally acting sympatholytic agents on the blood pressure response to renal denervation
Nolde, J. M., Kiuchi, M. G., Carnagarin, R., Ward, N. C., Wanten, M., Böhm, M., Mahfoud, F., Schmieder, R. E., Narkiewicz, K., & Schlaich, M. P. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004219 · Cited by 3
Self-citationIntervencijska radiologija: endovaskularna renalna denervacija u liječenju rezistentne hipertenzije
Perkov, D., & Padovan, R. Š. (2012) · Medix : specijalizirani medicinski dvomjesečnik
Zhang, D., Wang, D., Wang, X., Yu, J., & Liu, B. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1790873
“The kidney occupies a central position in the cardiorenal sympathetic axis, functioning as both an effector and amplifier of sympathetic signaling (29, 30).”
Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Arnott, C. G., & Patel, A. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00018-5
Rakhmadi, A. (2023) · Institutional Repositories DataBase (IRDB) · doi:10.20776/900122542
Renal Denervation for Congestive Heart Failure
Raphael, C. E., & Davies, J. E. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5223-1_20
Neural control of renal function
Grisk, O., Johns, E. J., & Kopp, U. C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-12-815389-5.00031-9
Individualizing Care in Resistant Hypertension: Lessons From Renal Denervation
Sharabi, Y. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26874
Li, M., Yang, D., Cheng, X., Wei, Q., & Zhang, D. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1844520
Komnenov, D., Uthman, Y., Ramirez, N., & Banek, C. T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.742819
Organ crosstalk in kidney diseases: Insights from metabolic, hormonal and nervous regulation
Lin, S., Zhu, S., & Fu, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124637
Jalalinezhad, A., Sharifi, M. R., Rezazadeh, H., & Soltani, N. (2026) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_1017_25
“RDN reduces sympathetic activity both locally in the kidney and systemically, [19,20] which in turn reduces renin activity and increases RBF [Figure 1].”
Shahverdi, E., Shahi, S., Schneider, C., & Lange, M. (2026) · Clinical Hypertension · doi:10.5646/ch.2026.32.e39
“20/ although these techniques currently remain unsuitable for routine clinical practice because of their technical complexity and limited availability [27,28,30,31,38,40,41,53-55, Evaluation of sympathetic target-organ involvement represents the subsequent component of patient phenotyping.”
Experimental studies on new therapeutic approaches in atrial fibrillation
Linz, D. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20131114dl
Resistant Hypertension: Epidemiological and Evolving Therapeutic Concepts
Grassi, G. M. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_3
“Third, the intervention allows to reduce sympathetic activity while also ameliorating the metabolic balance of glucose and insulin sensitivity values and favoring regression of left ventricular hypertrophy [27, 28].”
Background
Metadata
- Authors
- Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- University of Oklahoma Health Sciences Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-27
- Volume
- 361
- Issue
- 9
- Pages
- 932-934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994487234
- Cited by
- 772
- References
- 5
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 19 · 2023: 25 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 31 · 2017: 42 · 2016: 42 · 2015: 52 · 2014: 115 · 2013: 136 · 2012: 95
- FWCI
- 42.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- uncontrolled hypertension, bevacizumab, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation, intermittent dosing, long-term drug safety, iron requirements
- MeSH terms
- Humans, Hypertension, Kidney, Male, Middle Aged, Norepinephrine, Renal Artery, Sympathectomy, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.